Rhabdomyosarcoma, Alveolar
"Rhabdomyosarcoma, Alveolar" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of RHABDOMYOSARCOMA occurring mainly in adolescents and young adults, affecting muscles of the extremities, trunk, orbital region, etc. It is extremely malignant, metastasizing widely at an early stage. Few cures have been achieved and the prognosis is poor. "Alveolar" refers to its microscopic appearance simulating the cells of the respiratory alveolus. (Holland et al., Cancer Medicine, 3d ed, p2188)
| Descriptor ID |
D018232
|
| MeSH Number(s) |
C04.557.450.590.550.660.665 C04.557.450.795.550.660.665
|
| Concept/Terms |
Rhabdomyosarcoma, Alveolar- Rhabdomyosarcoma, Alveolar
- Alveolar Rhabdomyosarcoma
- Alveolar Rhabdomyosarcomas
- Rhabdomyosarcomas, Alveolar
- Rhabdomyosarcoma 2
|
Below are MeSH descriptors whose meaning is more general than "Rhabdomyosarcoma, Alveolar".
Below are MeSH descriptors whose meaning is more specific than "Rhabdomyosarcoma, Alveolar".
This graph shows the total number of publications written about "Rhabdomyosarcoma, Alveolar" by people in this website by year, and whether "Rhabdomyosarcoma, Alveolar" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 1996 | 2 | 0 | 2 |
| 2000 | 2 | 0 | 2 |
| 2001 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Rhabdomyosarcoma, Alveolar" by people in Profiles.
-
Thompson LDR, Jo VY, Agaimy A, Llombart-Bosch A, Morales GN, Machado I, Flucke U, Wakely PE, Miettinen M, Bishop JA. Sinonasal Tract Alveolar Rhabdomyosarcoma in Adults: A Clinicopathologic and Immunophenotypic Study of Fifty-Two Cases with Emphasis on Epithelial Immunoreactivity. Head Neck Pathol. 2018 Jun; 12(2):181-192.
-
Perez EA, Kassira N, Cheung MC, Koniaris LG, Neville HL, Sola JE. Rhabdomyosarcoma in children: a SEER population based study. J Surg Res. 2011 Oct; 170(2):e243-51.
-
Leventhal DD, Spiegel J, Keane W. Laryngeal alveolar rhabdomyosarcoma involving the true vocal fold in an adult: Case report. Ear Nose Throat J. 2010 Dec; 89(12):E8.
-
Corao DA, Biegel JA, Coffin CM, Barr FG, Wainwright LM, Ernst LM, Choi JK, Zhang PJ, Pawel BR. ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status. Pediatr Dev Pathol. 2009 Jul-Aug; 12(4):275-83.
-
Raney RB, Chintagumpala M, Anderson J, Pappo A, Qualman S, Wharam M, Wiener E, Meyer W. Results of treatment of patients with superficial facial rhabdomyosarcomas on protocols of the Intergroup Rhabdomyosarcoma Study Group (IRSG), 1984-1997. Pediatr Blood Cancer. 2008 May; 50(5):958-64.
-
Park JH, Hosalkar HS, Miller RE, Lackman RD. A rare case of osteosarcoma and rhabdomyosarcoma at the same site 7 years apart. Am J Orthop (Belle Mead NJ). 2008 Apr; 37(4):204-7.
-
Ehlers JP, Penne RB, Eagle RC, Carrasco JR. Alveolar rhabdomyosarcoma presenting as an acute orbital mass in the medial rectus muscle. Ophthalmic Plast Reconstr Surg. 2007 Mar-Apr; 23(2):149-51.
-
Fredericks WJ, Ayyanathan K, Rauscher FJ. Regulating the neoplastic phenotype using engineered transcriptional repressors. Cancer Lett. 2001 Jan; 162 Suppl:S23-S32.
-
Ayyanathan K, Fredericks WJ, Berking C, Herlyn M, Balakrishnan C, Gunther E, Rauscher FJ. Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene. Cancer Res. 2000 Oct 15; 60(20):5803-14.
-
Fredericks WJ, Ayyanathan K, Herlyn M, Friedman JR, Rauscher FJ. An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogene. Mol Cell Biol. 2000 Jul; 20(14):5019-31.